NASDAQ · Medical - Diagnostics & Research

Applied DNA Sciences, Inc. (APDN) Stock

$5.62 +31.62% NASDAQ: APDN Healthcare

Applied DNA Sciences, Inc. specializes in devising and marketing sophisticated DNA-centric technological solutions across diverse sectors.

Valuation

MetricValue
Price$5.62
Market Cap$7.26M
P/E Ratio-0.05
P/B Ratio4.51
P/S Ratio4.69
EPS (TTM)$-134.23
52-Week High$319.95
52-Week Low$2.13
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-652.52%
ROA-476.10%
ROCE-288.45%
Gross Margin59.89%
Operating Margin-800.00%
Net Margin-3450.00%
Debt/Equity0.00
Current Ratio1.82

Annual Financials (USD)

Metric20212022202320242025
Revenue$9.0M$18.0M$13.0M$3.0M$2.0M
Operating Profit$-12.0M$-14.0M$-11.0M$-14.0M$-16.0M
Net Profit$-16.0M$-8.0M$-10.0M$-7.0M$-69.0M
EPS$-46.35$-18.68$-15.21$-1.82$-134.23
Op Margin-136.2%-76.9%-81.9%-408.7%-750.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$14.0M$22.0M$14.0M$13.0M$4.0M
Total Liabilities$3.0M$9.0M$9.0M$4.0M$2.0M
Cash$7.0M$15.0M$7.0M$6.0M$2.0M
Borrowings$0$0$1.0M$1.0M$0

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-13.0M$-9.0M$-6.0M$-14.0M$-12.0M
Investing Cash Flow$-5.0M$-1.0M$-1.0M$-1.0M$0
Financing Cash Flow$3.0M$4.0M$1.0M$0$54.0M
Net Cash Flow$-1.0M$9.0M$-7.0M$-1.0M$-5.0M
Free Cash Flow$-16.0M$-9.0M$-6.0M$-14.0M$-13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.96
FCF Yield-183.77%
Quick Ratio1.74
Interest Coverage0.00
Return 1Y
Return 3Y
Return 5Y

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AFMDAffimed N.V. $0.18 +0.00% -0.02 $2.98M 0.00%
ARAVAravive, Inc. $0.04 -13.39% -0.02 $2.95M 0.00%
AWHAspira Women's Health Inc. $0.08 -15.90% -0.32 $2.46M 0.00%
BPTSBiophytis S.A. $8.22 -13.47% -0.57 $2.61M 0.00%
DMTKQDermTech, Inc. $0.00 0.00 $3496 0.00%

About Applied DNA Sciences, Inc.

Applied DNA Sciences, Inc. specializes in devising and marketing sophisticated DNA-centric technological solutions across diverse sectors. Its activities encompass nucleic acid-based in vitro diagnostics and the preclinical development and production of nucleic acid-based pharmaceuticals. Furthermore, the company offers robust solutions for bolstering supply chain security, combating counterfeiting, and preventing theft. Key offerings for product authenticity and supply chain integrity include SigNature molecular tags, which imbue products with forensic traceability and protection, thereby strengthening brand defense and supply chain resilience while aiding in criminal identification and prosecution. To facilitate real-time, field-based verification of these tags, they provide SigNify IF portable DNA readers along with corresponding SigNify consumable reagent test kits. The CertainT platform represents a holistic approach, integrating tagging, testing, and tracking capabilities, empowering manufacturers, brands, and trade organizations to substantiate their product claims with verifiable evidence. Within the diagnostic realm, the company produces the LineaTM COVID-19 Assay Kit, a PCR-based molecular diagnostic test. It also offers the safeCircle COVID-19 diagnostic kit, specifically designed to help curtail viral transmission within communal settings such as schools or workplaces. Additionally, Applied DNA Sciences delivers contract research and manufacturing services for the burgeoning nucleic acid-based therapeutic markets during their preclinical phases. This extends to providing contract research for clients involved in preclinical studies of RNA-based drugs and biologics. The company is also at the forefront of developing an innovative technology for the capture and identification of invasive circulating tumor cells, utilizing a proprietary functional assay to isolate live invasive tumor cells and their associated lymphocytes. Operating internationally, the firm maintains a significant footprint across the United States, Europe, and Asia. Founded in 1983, the organization was initially known as Datalink Systems, Inc., before officially changing its name to Applied DNA Sciences, Inc. in 2002. Its corporate headquarters are located in Stony Brook, New York.

Applied DNA Sciences, Inc. is headquartered in US.

Applied DNA Sciences, Inc. (APDN) stock trades at $5.62 with a market capitalization of $7.26M. The stock is valued at a price-to-earnings (P/E) ratio of -0.05, price-to-book of 4.51, price-to-sales of 4.69. Over the past 52 weeks the stock has ranged between $2.13 and $319.95, and currently trades 98.2% below its 52-week high.

On profitability, Applied DNA Sciences, Inc. generates a return on equity (ROE) of -652.52%, return on capital employed of -288.45%, an operating margin of -800.00%, a net profit margin of -3450.00%.

Official website: www.adnas.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides